• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

艾曲泊帕用于儿童血小板减少症的长期管理

Eltrombopag in long-term management of pediatric thrombocytopenia.

作者信息

Shah Sanjay J, Etzl Michael M

机构信息

Phoenix Children's Hospital Phoenix Arizona.

出版信息

Clin Case Rep. 2018 Dec 10;7(1):196-201. doi: 10.1002/ccr3.1916. eCollection 2019 Jan.

DOI:10.1002/ccr3.1916
PMID:30656041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6333124/
Abstract

Eltrombopag is a thrombopoietin receptor agonist that may be effective in a broad range of thrombocytopenias of distinct etiology. We have observed rapid, robust, and sustained responses to eltrombopag in two young patients with refractory thrombocytopenia, one with primary immune thrombocytopenia and the other with Evans syndrome.

摘要

艾曲泊帕是一种血小板生成素受体激动剂，可能对多种不同病因的血小板减少症有效。我们观察到两名难治性血小板减少症的年轻患者对艾曲泊帕有快速、强烈且持续的反应，其中一名患有原发性免疫性血小板减少症，另一名患有伊文氏综合征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d45b/6333124/c1be257024b1/CCR3-7-196-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d45b/6333124/06fdfa91f8d9/CCR3-7-196-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d45b/6333124/c1be257024b1/CCR3-7-196-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d45b/6333124/06fdfa91f8d9/CCR3-7-196-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d45b/6333124/c1be257024b1/CCR3-7-196-g002.jpg

相似文献

1
Eltrombopag in long-term management of pediatric thrombocytopenia.艾曲泊帕用于儿童血小板减少症的长期管理
Clin Case Rep. 2018 Dec 10;7(1):196-201. doi: 10.1002/ccr3.1916. eCollection 2019 Jan.
2
Successful treatment with thrombopoietin receptor agonist in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia.采用促血小板生成素受体激动剂治疗避免了慢性难治性免疫性血小板减少症患者行脾切除术。
Mediterr J Hematol Infect Dis. 2012;4(1):e2012003. doi: 10.4084/MJHID.2012.003. Epub 2012 Jan 18.
3
Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.依洛尤单抗：治疗抵抗性慢性原发免疫性血小板减少症的治疗药物。
Drugs. 2011 Jul 9;71(10):1333-53. doi: 10.2165/11207390-000000000-00000.
4
Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.聚焦于难治性慢性原发性免疫性血小板减少症的艾曲泊帕治疗。
BioDrugs. 2011 Dec 1;25(6):401-4. doi: 10.2165/11207620-000000000-00000.
5
Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales.在英格兰和威尔士，艾曲泊帕与罗米司亭治疗慢性免疫性血小板减少症的成本效益
Value Health. 2016 Jul-Aug;19(5):614-22. doi: 10.1016/j.jval.2016.03.1856. Epub 2016 May 11.
6
Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome.依鲁替尼改善干燥综合征患者的难治性血小板减少症。
Sci Prog. 2022 Apr-Jun;105(2):368504221102786. doi: 10.1177/00368504221102786.
7
Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial.依洛尤单抗治疗遗传性血小板减少症：一项 II 期临床试验。
Haematologica. 2020 Mar;105(3):820-828. doi: 10.3324/haematol.2019.223966. Epub 2019 Jul 4.
8
Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.艾曲泊帕：新型非肽类血小板生成素受体激动剂在免疫性血小板减少症治疗中的研究进展。
Ann Hematol. 2010 Jul;89 Suppl 1:67-74. doi: 10.1007/s00277-010-0953-x. Epub 2010 Apr 20.
9
Successful Use of Eltrombopag in a Pediatric Patient With Human Immunodeficiency Virus (HIV)-Associated Thrombocytopenia.艾曲泊帕在一名患有人免疫缺陷病毒（HIV）相关血小板减少症的儿科患者中的成功应用。
J Pediatr Pharmacol Ther. 2019 May-Jun;24(3):242-246. doi: 10.5863/1551-6776-24.3.242.
10
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.依鲁替尼治疗儿童慢性免疫性血小板减少症（PETIT2）的随机、多中心、安慰剂对照试验。
Lancet. 2015 Oct 24;386(10004):1649-58. doi: 10.1016/S0140-6736(15)61107-2. Epub 2015 Jul 28.

引用本文的文献

1
Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience.成人Evans综合征中血小板生成素受体激动剂：一项国际多中心经验
Blood. 2022 Aug 18;140(7):789-792. doi: 10.1182/blood.2022016818.
2
Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach.阐明艾曲泊帕在原发免疫性血小板减少症中所具有的免疫调节作用的作用机制：一种计算方法。
Int J Mol Sci. 2021 Jun 27;22(13):6907. doi: 10.3390/ijms22136907.
3
Interference of eltrombopag with bilirubin measurements on the Vitros 5600 analyzer.

本文引用的文献

1
Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.艾曲泊帕在临床实践中用于继发性免疫性血小板减少症。
Br J Haematol. 2017 Sep;178(6):959-970. doi: 10.1111/bjh.14788. Epub 2017 Jun 1.
2
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.艾曲泊帕添加至标准免疫抑制方案用于治疗再生障碍性贫血
N Engl J Med. 2017 Apr 20;376(16):1540-1550. doi: 10.1056/NEJMoa1613878.
3
Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.超越免疫性血小板减少症：血小板生成素受体激动剂不断演变的作用
依特罗泊帕格对 Vitros 5600 分析仪胆红素检测的干扰。
J Clin Lab Anal. 2021 Aug;35(8):e23796. doi: 10.1002/jcla.23796. Epub 2021 Jun 19.
4
Treatment-Free Remission in Chronic Idiopathic Thrombocytopenic Purpura.慢性特发性血小板减少性紫癜的无治疗缓解
Cureus. 2020 Jun 19;12(6):e8705. doi: 10.7759/cureus.8705.
Ann Hematol. 2017 Sep;96(9):1421-1434. doi: 10.1007/s00277-017-2953-6. Epub 2017 Mar 8.
4
Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation.揭示艾曲泊帕通过激活AKT/ERK依赖性途径促进人类巨核细胞生成。
Haematologica. 2016 Dec;101(12):1479-1488. doi: 10.3324/haematol.2016.146746. Epub 2016 Aug 11.
5
Sports Participation in Children and Adolescents with Immune Thrombocytopenia (ITP).免疫性血小板减少症（ITP）患儿及青少年的体育活动参与情况
Pediatr Blood Cancer. 2015 Dec;62(12):2223-5. doi: 10.1002/pbc.25644. Epub 2015 Jul 14.
6
The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy.长期全身性糖皮质激素治疗相关毒性的预测与监测。
Curr Rheumatol Rep. 2015 Jun;17(6):513. doi: 10.1007/s11926-015-0513-4.
7
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.在原发性免疫性血小板减少症患者完全缓解后成功停用艾曲泊帕。
Am J Hematol. 2015 Mar;90(3):E40-3. doi: 10.1002/ajh.23900. Epub 2015 Jan 16.
8
Health-related quality of life in children with newly diagnosed immune thrombocytopenia.新诊断免疫性血小板减少症患儿的健康相关生活质量
Haematologica. 2014 Sep;99(9):1525-31. doi: 10.3324/haematol.2014.106963. Epub 2014 Jun 20.
9
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.依鲁替尼可恢复对药物停药后可维持缓解的难治性重型再生障碍性贫血的三系造血。
Blood. 2014 Mar 20;123(12):1818-25. doi: 10.1182/blood-2013-10-534743. Epub 2013 Dec 17.
10
Positioning new treatments in the management of immune thrombocytopenia.定位新疗法在免疫性血小板减少症管理中的作用。
Pediatr Blood Cancer. 2013;60 Suppl 1(Suppl 1):S19-22. doi: 10.1002/pbc.24341. Epub 2012 Oct 25.